Duality Biologics announces B7H4 ADC milestone achievement and license exercise by BeiGene

CAR-T Digest - August 2020

30 Dec 2024: Duality Biologics announces B7H4 ADC milestone achievement and license exercise by BeiGene

BeiGene has exercised its exclusive option to the B7-H4 ADC DB1312/BG-C9074 from Duality Biologics, gaining global development, manufacturing, and commercialization rights for the investigational product
DualityBio received an option exercise fee and a milestone payment in 2024 based on the Phase I dose-escalation advancement of DB1312/BG-C9074
In July 2023, DualityBio entered into an agreement with BeiGene, granting them an exclusive option for a global clinical and commercial license to a preclinical ADC therapy targeting solid tumors
Under the agreement, DualityBio received an upfront payment and is eligible for up to $1.3 billion in additional payments based on BeiGene’s exercise of the option and the achievement of various milestones, along with tiered royalties